Jason Hodde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jason Hodde has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Francis Badylak
McGowan Institute for Regenerative Medicine, University of Pittsburgh
3 shared publications Abram Janis
Cook Biotech Incorporated
2 shared publicationsMichael Hiles
Cook Biotech Incorporated
2 shared publicationsChad E Johnson
1 shared publicationChad Johnson
Cook Biotech Incorporated
1 shared publicationChad S McAlexander
1 shared publication
Latest Publications
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Tissue Viability
- Vol. 29 (1) , 42-47
Characterization of the local wound environment following treatment of chronic leg ulcers with SIS wound matrix
- 1 February 2020
- Published by Elsevier in Journal of Tissue Viability
- Vol. 29 (1) , 42-47
Open AccessCharacterization of the local wound environment following treatment of chronic leg ulcers with SIS wound matrix
- Open Access
- 30 April 2014
- Published by Springer Nature in BMC Surgery
- Vol. 14 (1) , 25
Abdominal wall reconstruction with components separation and mesh reinforcement in complex hernia repair
Abdominal closure in the presence of enterocutaneous fistula, stoma or infection can be challenging. A single-surgeon’s experience of performing components separation abdominal reconstruction and reinforcement with mesh in the difficult abdomen is presented.
- 30 April 2014
- Published by Springer Nature in BMC Surgery
- Vol. 14 (1) , 25
Open AccessAbdominal wall reconstruction with components separation and mesh reinforcement in complex hernia repair
Abdominal closure in the presence of enterocutaneous fistula, stoma or infection can be challenging. A single-surgeon’s experience of performing components separation abdominal reconstruction and reinforcement with mesh in the difficult abdomen is presented.
- 1 April 2007
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 18 (4) , 545-550
Effects of sterilization on an extracellular matrix scaffold: Part II. Bioactivity and matrix interaction
Small intestinal submucosa (SIS) has been successfully used to treat a variety of damaged or diseased tissues in human patients. As a biologic scaffold, SIS stimulates repair of damaged or diseased tissues and organs with tissue that is similar in structure and function to the material it was meant to replace. To meet clinical safety requirements, biologic materials from animal tissues must undergo processing treatments to minimize host immune response and to eliminate the possibility of disease transmission. The effect of peracetic acid disinfection, lyophilization, and ethylene oxide sterilization on the in vitro bioactivity of the processed SIS was therefore examined in murine fibroblasts and pheochromocytoma (PC12) cells. Specifically, the ability of processed SIS to support fibroblast attachment, to stimulate PC12 cell differentiation, and to upregulate fibroblast VEGF secretion was examined. Fibroblasts attach to the sterilized SIS, remain viable, and more than double their secretion of VEGF as a result of interacting with the SIS matrix components. Additionally, PC12 cells exhibit increased neurite outgrowth following stimulation by SIS matrix proteins versus controls. We conclude that a biologic scaffold can be prepared for human use and still retain significant bioactivity.
- 1 April 2007
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 18 (4) , 545-550
Effects of sterilization on an extracellular matrix scaffold: Part II. Bioactivity and matrix interaction
Small intestinal submucosa (SIS) has been successfully used to treat a variety of damaged or diseased tissues in human patients. As a biologic scaffold, SIS stimulates repair of damaged or diseased tissues and organs with tissue that is similar in structure and function to the material it was meant to replace. To meet clinical safety requirements, biologic materials from animal tissues must undergo processing treatments to minimize host immune response and to eliminate the possibility of disease transmission. The effect of peracetic acid disinfection, lyophilization, and ethylene oxide sterilization on the in vitro bioactivity of the processed SIS was therefore examined in murine fibroblasts and pheochromocytoma (PC12) cells. Specifically, the ability of processed SIS to support fibroblast attachment, to stimulate PC12 cell differentiation, and to upregulate fibroblast VEGF secretion was examined. Fibroblasts attach to the sterilized SIS, remain viable, and more than double their secretion of VEGF as a result of interacting with the SIS matrix components. Additionally, PC12 cells exhibit increased neurite outgrowth following stimulation by SIS matrix proteins versus controls. We conclude that a biologic scaffold can be prepared for human use and still retain significant bioactivity.
- 1 April 2007
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 18 (4) , 537-543
Effects of sterilization on an extracellular matrix scaffold: Part I. Composition and matrix architecture
The impact of peracetic acid (PAA), lyophilization, and ethylene oxide (EO) sterilization on the composition and three dimensional matrix structure of small intestinal submucosa (SIS), a biologic scaffold used to stimulate the repair of damaged tissues and organs, was examined. Fibronectin and glycosaminoglycans are retained in SIS following oxidation by peracetic acid and alkylation using ethylene oxide gas. Significant amounts of FGF-2 are also retained, but VEGF is susceptible to the effects of PAA and is dramatically reduced following processing. Further, matrix oxidation, lyophilization, and sterilization with EO can be performed without irreversibly collapsing the three dimensional structure of the native SIS. These structural features and growth promoting extracellular matrix constituents are likely to be important variables underlying cellular attachment, infiltration and eventual incorporation of SIS into healing host tissues.
- 1 April 2007
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 18 (4) , 537-543
Effects of sterilization on an extracellular matrix scaffold: Part I. Composition and matrix architecture
The impact of peracetic acid (PAA), lyophilization, and ethylene oxide (EO) sterilization on the composition and three dimensional matrix structure of small intestinal submucosa (SIS), a biologic scaffold used to stimulate the repair of damaged tissues and organs, was examined. Fibronectin and glycosaminoglycans are retained in SIS following oxidation by peracetic acid and alkylation using ethylene oxide gas. Significant amounts of FGF-2 are also retained, but VEGF is susceptible to the effects of PAA and is dramatically reduced following processing. Further, matrix oxidation, lyophilization, and sterilization with EO can be performed without irreversibly collapsing the three dimensional structure of the native SIS. These structural features and growth promoting extracellular matrix constituents are likely to be important variables underlying cellular attachment, infiltration and eventual incorporation of SIS into healing host tissues.
- 1 January 2007
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 107 (6) , 641-547
Constructive Soft Tissue Remodelling with a Biologic Extracellular Matrix Graft: Overview and Review of the Clinical Literature
The extracellular matrix directs all phases of healing following trauma or disease and is therefore nature’s ideal scaffold material. When used strategically to induce the repair and restoration of soft tissues following surgery, exogenous extracellular matrix scaffolds interact with surrounding tissues and cells to form a permanent repair without leaving behind a permanent material that can result in chronic inflammation or infection. Biomaterials derived from natural extracellular matrix, such as Surgisis® (Cook Medical Incorporated, Bloomington, IN, USA), provide the extracellular components necessary to direct the healing response, allow for the reconstruction of new, healthy tissue and restore mechanical and functional integrity to the damaged site. The 3-dimensional organization of these extracellular components distinguishes the Surgisis mesh from synthetic materials and is associated with better long-term repairs. The tissue response to this biologic mesh is discussed in the context of recent reports on successful clinical applications.
- 1 January 2007
- Published by Taylor & Francis in Acta Chirurgica Belgica
- Vol. 107 (6) , 641-547
Constructive Soft Tissue Remodelling with a Biologic Extracellular Matrix Graft: Overview and Review of the Clinical Literature
The extracellular matrix directs all phases of healing following trauma or disease and is therefore nature’s ideal scaffold material. When used strategically to induce the repair and restoration of soft tissues following surgery, exogenous extracellular matrix scaffolds interact with surrounding tissues and cells to form a permanent repair without leaving behind a permanent material that can result in chronic inflammation or infection. Biomaterials derived from natural extracellular matrix, such as Surgisis® (Cook Medical Incorporated, Bloomington, IN, USA), provide the extracellular components necessary to direct the healing response, allow for the reconstruction of new, healthy tissue and restore mechanical and functional integrity to the damaged site. The 3-dimensional organization of these extracellular components distinguishes the Surgisis mesh from synthetic materials and is associated with better long-term repairs. The tissue response to this biologic mesh is discussed in the context of recent reports on successful clinical applications.
- 1 January 2007
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 8 (2) , 61-66
Extracellular Matrix as a Strategy for Treating Chronic Wounds
The dermis normally directs all phases of skin wound healing following tissue trauma or disease. However, in chronic wounds, the dermal matrix is insufficient to stimulate healing and assistance by external factors is needed for wound closure. Although the concept of the extracellular matrix directing wound healing is not new, ideas about how best to provide the extracellular matrix components required to ‘jump-start’ the healing process are still evolving. Historically, these strategies have included use of enzyme-inhibiting dressing materials, which bind matrix metalloproteinases and remove them from the chronic wound environment, or direct application of purified growth factors to stimulate fibroblast activity and deposition of neo-matrix. More recently, the application of a structurally intact, biochemically complex extracellular matrix, designed to provide the critical extracellular components of the dermis in a single application, has allowed for the reconstruction of new, healthy tissue and restoration of tissue integrity in the previously chronic wound. This review focuses on this third mechanism as an emerging tactic in effective wound repair. Intact extracellular matrix can quickly, easily, and effectively provide key extracellular components of the dermis necessary to direct the healing response and allow for the proliferation of new, healthy tissue. Its application may promote the healing of wounds that have been refractory to other, more conventional treatment strategies, and may eventually show utility when used earlier in wound healing treatment with the goal of preventing wounds from reaching a truly chronic, nonresponsive state.
- 1 January 2007
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 8 (2) , 61-66
Extracellular Matrix as a Strategy for Treating Chronic Wounds
The dermis normally directs all phases of skin wound healing following tissue trauma or disease. However, in chronic wounds, the dermal matrix is insufficient to stimulate healing and assistance by external factors is needed for wound closure. Although the concept of the extracellular matrix directing wound healing is not new, ideas about how best to provide the extracellular matrix components required to ‘jump-start’ the healing process are still evolving. Historically, these strategies have included use of enzyme-inhibiting dressing materials, which bind matrix metalloproteinases and remove them from the chronic wound environment, or direct application of purified growth factors to stimulate fibroblast activity and deposition of neo-matrix. More recently, the application of a structurally intact, biochemically complex extracellular matrix, designed to provide the critical extracellular components of the dermis in a single application, has allowed for the reconstruction of new, healthy tissue and restoration of tissue integrity in the previously chronic wound. This review focuses on this third mechanism as an emerging tactic in effective wound repair. Intact extracellular matrix can quickly, easily, and effectively provide key extracellular components of the dermis necessary to direct the healing response and allow for the proliferation of new, healthy tissue. Its application may promote the healing of wounds that have been refractory to other, more conventional treatment strategies, and may eventually show utility when used earlier in wound healing treatment with the goal of preventing wounds from reaching a truly chronic, nonresponsive state.
- 18 December 2006
- Published by Wiley in Anz Journal of Surgery
- Vol. 76 (12) , 1096-1100
EXTRACELLULAR MATRIX AS A BIOACTIVE MATERIAL FOR SOFT TISSUE RECONSTRUCTION
The extracellular matrix (ECM) directs all phases of healing following trauma or disease and is therefore a natural source of prosthetic mesh material that can be used strategically to induce the repair and restoration of soft tissues following surgery. Biomaterials such as Surgisis® (Cook Biotech Incorporated, West Lafayette, IN, USA), which are derived from natural ECM, provide the extracellular components necessary to direct the healing response, allow for the proliferation of new, healthy tissue and restore tissue integrity to the damaged site. The 3‐D organization of these extracellular components distinguishes the Surgisis® mesh from synthetic materials and is associated with constructive tissue remodelling instead of scar tissue. Common features of this ECM‐assisted tissue remodelling include angiogenesis, recruitment of circulating progenitor cells and constructive remodelling of damaged tissue structures. The tissue response to this biologic mesh is discussed in the context of recent reports on clinical hernia repair.
- 18 December 2006
- Published by Wiley in Anz Journal of Surgery
- Vol. 76 (12) , 1096-1100
EXTRACELLULAR MATRIX AS A BIOACTIVE MATERIAL FOR SOFT TISSUE RECONSTRUCTION
The extracellular matrix (ECM) directs all phases of healing following trauma or disease and is therefore a natural source of prosthetic mesh material that can be used strategically to induce the repair and restoration of soft tissues following surgery. Biomaterials such as Surgisis® (Cook Biotech Incorporated, West Lafayette, IN, USA), which are derived from natural ECM, provide the extracellular components necessary to direct the healing response, allow for the proliferation of new, healthy tissue and restore tissue integrity to the damaged site. The 3‐D organization of these extracellular components distinguishes the Surgisis® mesh from synthetic materials and is associated with constructive tissue remodelling instead of scar tissue. Common features of this ECM‐assisted tissue remodelling include angiogenesis, recruitment of circulating progenitor cells and constructive remodelling of damaged tissue structures. The tissue response to this biologic mesh is discussed in the context of recent reports on clinical hernia repair.
- 1 January 2005
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 14 (1) , 23-25
An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix
Objective: To examine the retention and bioactivity of endogenous FGF-2 after prolonged storage within a complex matrix. FGF-2 is a growth factor found in Oasis Wound Matrix, a purified collagen wound-care product containing other endogenous components of the extracellular matrix. Method: FGF-2 content was measured by ELISA. FGF-2 activity was measured using an in vitro bioassay in rat pheochromocytoma (PC12) cells. Results: FGF-2 content ranged from 15.3ng/g to 84.3ng/g. The bioassay showed that the FGF-2 retained in the matrix was present in a bioactive form able to cause differentiation of cells in culture Conclusion: The results demonstrate that wound-care products can be developed to retain their bioactivity over time and that inherently unstable purified growth factors are preserved if stored as bound factors within their natural extracellular matrix. The results also suggest that use of acellular matrices containing active growth factors would have advantages in terms of simplicity and cost over purified recombinant growth factor therapies. Declaration of interest: This study was supported by Cook Biotech Inc, West Lafayette, USA.
- 1 January 2005
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 14 (1) , 23-25
An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix
Objective: To examine the retention and bioactivity of endogenous FGF-2 after prolonged storage within a complex matrix. FGF-2 is a growth factor found in Oasis Wound Matrix, a purified collagen wound-care product containing other endogenous components of the extracellular matrix. Method: FGF-2 content was measured by ELISA. FGF-2 activity was measured using an in vitro bioassay in rat pheochromocytoma (PC12) cells. Results: FGF-2 content ranged from 15.3ng/g to 84.3ng/g. The bioassay showed that the FGF-2 retained in the matrix was present in a bioactive form able to cause differentiation of cells in culture Conclusion: The results demonstrate that wound-care products can be developed to retain their bioactivity over time and that inherently unstable purified growth factors are preserved if stored as bound factors within their natural extracellular matrix. The results also suggest that use of acellular matrices containing active growth factors would have advantages in terms of simplicity and cost over purified recombinant growth factor therapies. Declaration of interest: This study was supported by Cook Biotech Inc, West Lafayette, USA.
- 1 August 2004
- Published by Elsevier in Journal of Surgical Research
- Vol. 120 (2) , 189-194
Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats
- 1 August 2004
- Published by Elsevier in Journal of Surgical Research
- Vol. 120 (2) , 189-194
Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats
- 1 January 2004
- Vol. 10 (1) , PI1-5
A comparison of suture retention strengths for three biomaterials.
The suture holding capacity, suture retention strength, and burst strength of three biomaterials (Marlex), SIS, and PeriGuard) were evaluated to compare their performance characteristics in an ex vivo setting representing the immediate postoperative period. A circular defect was created in the fascial tissue of the abdominal aponeurosis collected from normal dogs. Defects were repaired with either Marlex (polypropylene mesh), Periguard (bovine pericardium) or small intestinal submucosa (SIS) using 2-0 prolene and a 1.0-cm suture bite. The force required to induce failure at the repair site was recorded as the suture-holding capacity. Suture retention strength was calculated as the load distribution over the specimen cross-section in contact with the suture at the time of rupture. Burst strength of the raw materials was also measured. The suture-holding capacity was 370.9+/-56.2 N for Marlex; 214.3+/-36.1 N for Periguard, and 287.9+/-34.3 N for SIS. The suture retention strengths were: Marlex, 413.4+/-59.7 N/mm2; Periguard, 97.0+/-20.1 N/mm2; and SIS, 106.9+/-12.7 N/mm2. The burst strength of Marlex, Periguard and SIS were 476.7+/-50.8 N, 432.12+/-82.1 N, and 433.6+/-79.5 N respectively. All three materials provide adequate strength and suture-holding capacities to be of use in the repair of soft tissue defects.
- 1 January 2004
- Vol. 10 (1) , PI1-5
A comparison of suture retention strengths for three biomaterials.
The suture holding capacity, suture retention strength, and burst strength of three biomaterials (Marlex), SIS, and PeriGuard) were evaluated to compare their performance characteristics in an ex vivo setting representing the immediate postoperative period. A circular defect was created in the fascial tissue of the abdominal aponeurosis collected from normal dogs. Defects were repaired with either Marlex (polypropylene mesh), Periguard (bovine pericardium) or small intestinal submucosa (SIS) using 2-0 prolene and a 1.0-cm suture bite. The force required to induce failure at the repair site was recorded as the suture-holding capacity. Suture retention strength was calculated as the load distribution over the specimen cross-section in contact with the suture at the time of rupture. Burst strength of the raw materials was also measured. The suture-holding capacity was 370.9+/-56.2 N for Marlex; 214.3+/-36.1 N for Periguard, and 287.9+/-34.3 N for SIS. The suture retention strengths were: Marlex, 413.4+/-59.7 N/mm2; Periguard, 97.0+/-20.1 N/mm2; and SIS, 106.9+/-12.7 N/mm2. The burst strength of Marlex, Periguard and SIS were 476.7+/-50.8 N, 432.12+/-82.1 N, and 433.6+/-79.5 N respectively. All three materials provide adequate strength and suture-holding capacities to be of use in the repair of soft tissue defects.